Comparison of 80 versus 10 mg of Atorvastatin on Occurrence of Cardiovascular Events After the First Event (from the Treating to New Targets [TNT] Trial)
December 23rd, 2009 Posted by: admin
Publication year: 2009
Source: The American Journal of Cardiology, In Press, Corrected Proof, Available online 22 December 2009
John C., LaRosa , Prakash C., Deedwania , James, Shepherd , Nanette K., Wenger , Heiner, Greten , …
Analyses of randomized clinical trials are usually restricted to examination of time to first event. However, because many patients have multiple events, this approach precludes much potentially useful clinical and economic data. To assess the effect on overall disease burden in the Treating to New Targets (TNT) study, we evaluated the effect of treatment with atorvastatin 80 versus 10 mg in the period after the occurrence of a first cardiovascular event. In TNT, 10,001 patients with stable coronary heart disease received double-blind therapy with atorvastatin 80 or 10 mg and were followed for 4.9 years. Post hoc time-to-event analysis was…
